A2AAdenosine Receptor Gene Deletion or Synthetic A2AAntagonist Liberate Tumor-Reactive CD8+T Cells from Tumor-Induced Immunosuppression

Current and experimental treatments of Parkinson disease: A guide for neuroscientists

(2016) Wolfgang Oertel et al.   JOURNAL OF NEUROCHEMISTRY

Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases

(2016) Bruce N. Cronstein et al.   Nature Reviews Rheumatology

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

(2016) Vinit Kumar et al.   TRENDS IN IMMUNOLOGY

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

(2015) Stefano Ugel et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunological mechanisms of the antitumor effects of supplemental oxygenation

(2015) Stephen M. Hatfield et al.   Science Translational Medicine

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

(2015) Roberto Bellucci et al.   OncoImmunology

Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice

(2014) Karen M. Smith et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

(2014) Stephen M. Hatfield et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists

(2014) M. V. Sitkovsky et al.   Cancer Immunology Research

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth

(2013) Melanie Mediavilla-Varela et al.   CANCER BIOLOGY & THERAPY

Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions

(2013) Adolfo Ramirez-Zamora et al.   Expert Review of Neurotherapeutics

Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible

(2013) Akio Ohta et al.   INTERNATIONAL IMMUNOLOGY

Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer

(2013) Michail Sitkovsky et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Purinergic Signaling during Inflammation

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents

(2013) Koji Yamada et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors

(2013) Paul A. Beavis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adenosine A2A receptor antagonism and genetic deletion attenuate the effects of dopamine D2 antagonism on effort-based decision making in mice

(2012) M. Pardo et al.   NEUROPHARMACOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway

(2012) Akio Ohta et al.   Frontiers in Immunology

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

(2011) Adam T. Waickman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors

(2011) C. Cekic et al.   JOURNAL OF IMMUNOLOGY

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors--An Update

(2011) B. B. Fredholm et al.   PHARMACOLOGICAL REVIEWS

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders

(2010) Robert A. Hodgson et al.   EXPERIMENTAL NEUROLOGY

Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases

(2010) G. Liu et al.   JOURNAL OF IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vitroinduction of T cells that are resistant to A2adenosine receptor-mediated immunosuppression

(2009) Akio Ohta et al.   BRITISH JOURNAL OF PHARMACOLOGY

A2A adenosine receptor (AR) activation inhibits pro-inflammatory cytokine production by human CD4+ helper T cells and regulates Helicobacter-induced gastritis and bacterial persistence

(2009) M S Alam et al.   Mucosal Immunology

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

(2008) M. Ahmadzadeh et al.   BLOOD

Hypoxia-Adenosinergic Immunosuppression: Tumor Protection by T Regulatory Cells and Cancerous Tissue Hypoxia

(2008) M. V. Sitkovsky et al.   CLINICAL CANCER RESEARCH

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines

(2008) Masahisa Jinushi et al.   IMMUNOLOGICAL REVIEWS

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS